慢性炎症与衰弱的研究进展^*

Research advances in chronic inflammation and frailty

摘要

慢性炎症与衰弱已成为老年医学领域关注的热点。本文综述了该领域的研究进展, 首先概述衰弱的定义与评估工具, 进而探讨慢性炎症与衰弱相互作用的潜在机制, 重点分析了主要炎症标志物如C反应蛋白 (CRP)、白细胞介素-6 (IL-6)、肿瘤坏死因子-α (TNF-α) 及生物标志物组合在衰弱中的角色与研究进展。本文旨在为构建基于炎症调控的衰弱早期识别与干预策略提供理论依据, 对改善老年健康预后具有重要的临床指导意义。

Abstract

Chronic inflammation and frailty have emerged as key focal points in the field of geriatric medicine. This review summarizes the research progress on chronic inflammation and frailty, encompassing definitions and assessment methods of frailty, mechanistic discussions on their interplay, and advances in key inflammatory biomarkers such as C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and biomarker panels. The review aims to provide a theoretical foundation for establishing prevention and intervention systems targeting frailty through inflammation-modulating strategies, and it has important clinical guiding significance for improving the health prognosis of the elderly.

关键词

慢性炎症 / 衰弱 / C反应蛋白 / 白细胞介素-6 / 肿瘤坏死因子-α / 生物标志物组合

Key words

Chronic inflammation / Frailty / C-reactive protein / Interleukin-6 / Tumor necrosis factor-α / Biomarker panel

参考文献

[1] Hoogendijk E O, Afilalo J, Ensrud K E, et al. Frailty: implications for clinical practice and public health [J]. Lancet, 2019, 394(10206): 1365-1375.

[2] Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty [J]. Nat Rev Cardiol, 2018, 15(9): 505-522.

[3] Coperchini F, Greco A, Teliti M, et al. Inflamm—ageing: how cytokines and nutrition shape the trajectory of ageing [J]. Cytokine Growth Factor Rev, 2025, 82: 31-42.

[4] Orisaka M, Mizutani T, Miyazaki Y, et al. Chronic low—grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging [J]. Front Endocrinol, 2023, 14: 1324429.

[5] Fried L P, Tangen C M, Walston J, et al. Frailty in older adults: evidence for a phenotype [J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M146-M157.

[6] Morley J E, Vellas B, van Kan G A, et al. Frailty consensus: a call to action [J]. J Am Med Dir Assoc, 2013, 14(6): 392-397.

[7] Thillainadesan J, Scott I A, Le Couteur D G. Frailty, a multisystem ageing syndrome [J]. Age Ageing, 2020, 49(5): 758-763.

[8] Franceschi C, Bonafè M, Valensin S, et al. Inflamm—aging. An evolutionary perspective on immunosenescence [J]. Ann N Y Acad Sci, 2000, 908(1): 244-254.

[9] Marcos—Pérez D, Sánchez—Flores M, Proietti S, et al. Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta—analysis [J]. Geroscience, 2020, 42(6): 1451-1473.

[10] Li X, Li C, Zhang W, et al. Inflammation and aging: signaling pathways and intervention therapies [J]. Signal Transduction Targeted Ther, 2023, 8(1): 1-29.

[11] Zhang L, Zeng X, He F, et al. Inflammatory biomarkers of frailty: a review [J]. Exp Gerontol, 2023, 179: 112253.

[12] Marcos—Pérez D, Sánchez—Flores M, Maseda A, et al. Frailty in older adults is associated with plasma concentrations of inflammatory mediators but not with lymphocyte subpopulations [J]. Front Immunol, 2018, 9: 1056.

[13] Kang M G, Jung H W, Kim B J. A link between systemic low—grade inflammation and frailty in older adults: clinical evidence from a nationwide population—based study [J]. Korean J Intern Med, 2024, 39(6): 1011-1020.

[14] He L, Yang J, Fang Y. Longitudinal analysis on inflammatory markers and frailty progression: based on the English longitudinal study of aging [J]. Eur Geriatr Med, 2024, 15(5): 1323-1330.

[15] Bålsrud P, Ulven S M, Christensen J J, et al. Inflammatory markers and frailty in home—dwelling elderly, a cross—sectional study [J]. BMC Geriatr, 2024, 24(1): 175.

[16] McKechnie D. G. J, Papacosta A. O, Lennon L. T, et al. Associations between inflammation, cardiovascular biomarkers and incident frailty: the British Regional Heart Study [J]. Age Ageing, 2021, 50(6): 1979-1987.

[17] McKechnie D. G. J, Patel M, Papacosta A. O, et al. Associations between inflammation, coagulation, cardiac strain and injury, and subclinical vascular disease with frailty in older men: a cross—sectional study [J]. BMC Geriatr, 2022, 22(1): 405.

[18] Luo Y F, Cheng Z J, Wang Y F, et al. Unraveling the relationship between high—sensitivity C—reactive protein and frailty: evidence from longitudinal cohort study and genetic analysis [J]. BMC Geriatr, 2024, 24(1): 222.

[19] Bålsrud P, Ulven S M, Ottestad I, et al. Association between inflammatory markers, body composition and frailty in home—dwelling elderly: an 8—year follow—up study [J]. Geroscience, 2024, 46(6): 5629-5641.

[20] Tuttle C S L, Thang L A N, Maier A B. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta—analysis [J]. Ageing Res Rev, 2020, 64: 101185.

[21] Picca A, Coelho—Junior H J, Calvani R, et al. Biomarkers shared by frailty and sarcopenia in older adults: a systematic review and meta—analysis [J]. Ageing Res Rev, 2022, 73: 101530.

[22] Buchmann N, Fielitz J, Spira D, et al. Muscle mass and inflammation in older adults: impact of the metabolic syndrome [J]. Gerontology, 2022, 68(9): 989-998.

[23] Kochlik B, Franz K, Henning T, et al. Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi—morbid patients [J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 157-166.

[24] Byrne T, Cooke J, Bambrick P, et al. Circulating inflammatory biomarker responses in intervention trials in frail and sarcopenic older adults: a systematic review and meta—analysis [J]. Exp Gerontol, 2023, 177: 112199.

[25] Sepulveda M, Arauna D, Garcia F, et al. Frailty in aging and the search for the optimal biomarker: a review [J]. Biomedicines, 2022, 10(6): 1426.

[26] Tylutka A, Walas Ł, Zembron—Lacny A. Level of IL—6, TNF, and IL—1β and age—related diseases: a systematic review and meta—analysis [J]. Front Immunol, 2024, 15: 1330386.

[27] Asoudeh F, Dashti F, Raeesi S, et al. Inflammatory cytokines and sarcopenia in Iranian adults—results from SARIR study [J]. Sci Rep, 2022, 12(1): 5471.

[28] Tran Van Hoi E, De Glas N A, Portielje J E A, et al. Biomarkers of the ageing immune system and their association with frailty—A systematic review [J]. Exp Gerontol, 2023, 176: 112163.

[29] Tang Y, Zhai Y, Song W, et al. Association between complete blood count—derived inflammatory markers and the risk of frailty and mortality in middle—aged and older adults [J]. Front Public Health, 2024, 12: 1427546.

[30] Zhang H, Liu X, Wang X, et al. Association of two novel systemic inflammatory biomarkers and frailty based on NHANES 2007—2018 [J]. Front Public Health, 2024, 12: 1377408.

[31] Zhang Q, Wang Z, Song M, et al. Effects of systemic inflammation and frailty on survival in elderly cancer patients: Results from the INSCOC study [J]. Front Immunol, 2023, 14: 936904.

[32] Okyar Baş A, Güner M, Ceylan S, et al. Pan—immune inflammation value; a novel biomarker reflecting inflammation associated with frailty [J]. Aging Clin Exp Res, 2023, 35(8): 1641-1649.

[33] Asik Z, Özen M. Evaluation of frailty and neutrophil—to—lymphocyte and platelet—to—lymphocyte ratios relationship in elderly people [J]. Nagoya J Med Sci, 2022, 84(1): 101-110.

[34] Wan X, Ji Y, Wang R, et al. Association between systemic immune—inflammation index and sarcopenic obesity in middle—aged and elderly Chinese adults: a cross—sectional study and mediation analysis [J]. Lipids Health Dis, 2024, 23(1): 230.

[35] Zheng Z, Luo H, Xue Q. U—shaped association of systemic immune—inflammation index levels with cancer—related and all—cause mortality in middle—aged and older individuals with frailty [J]. Arch Gerontol Geriat, 2024, 116: 105228.

基金资助

^*陕西省重点研发计划项目(2024SF-ZDCYL-01-12)